Regeneron Pharmaceuticals

Regeneron Pharmaceuticals logo
🇺🇸United States
Ownership
Public
Established
1988-01-01
Employees
13.4K
Market Cap
$132.4B
Website
http://www.regeneron.com
Introduction

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

REGN7257 in Adult Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy

Phase 1
Suspended
Conditions
Interventions
First Posted Date
2020-06-01
Last Posted Date
2024-12-20
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
33
Registration Number
NCT04409080
Locations
🇺🇸

Cleveland Clinic Foundation, Cleveland, Ohio, United States

🇺🇸

The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

🇫🇷

Hopital Saint-Louis - APHP, Paris, Ile-de-France, France

and more 7 locations

Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)

First Posted Date
2020-05-19
Last Posted Date
2024-08-27
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
102
Registration Number
NCT04394351
Locations
🇨🇦

Regeneron Study Site, London, Ontario, Canada

Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19

Phase 2
Completed
Conditions
Interventions
First Posted Date
2020-03-19
Last Posted Date
2021-09-23
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
1912
Registration Number
NCT04315298
Locations
🇺🇸

Regeneron Study Site, Renton, Washington, United States

🇺🇸

Regeneron Study Site 1, New York, New York, United States

🇺🇸

Regeneron Study Site 2, New York, New York, United States

Registry of Asthma Patients Initiating DUPIXENT®

Active, not recruiting
Conditions
First Posted Date
2020-02-27
Last Posted Date
2023-11-07
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
718
Registration Number
NCT04287621
Locations
🇺🇸

Clinical Research Specialists, LLC, Kissimmee, Florida, United States

🇺🇸

NorthShore University Health System, Evanston, Illinois, United States

🇺🇸

Northwell Health Division of Allergy & Immunology, Great Neck, New York, United States

and more 125 locations

Observational Study of Conjunctivitis in the Setting of DUPIXENT® Treatment for Atopic Dermatitis

Completed
Conditions
Interventions
First Posted Date
2020-02-27
Last Posted Date
2023-04-28
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
50
Registration Number
NCT04287608
Locations
🇺🇸

Regeneron Study Site, Houston, Texas, United States

Evaluate the Efficacy and Safety of Evinacumab in Pediatric Patients With Homozygous Familial Hypercholesterolemia

Phase 3
Completed
Conditions
Interventions
First Posted Date
2020-01-18
Last Posted Date
2024-07-16
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
20
Registration Number
NCT04233918
Locations
🇨🇳

Regeneron Research Center, Taipei, Taiwan

🇺🇦

Regeneron Research Site, Kyiv, Ukraine

Open-Label Efficacy and Safety Study of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy (CHAPLE Disease)

First Posted Date
2019-12-24
Last Posted Date
2024-05-13
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
10
Registration Number
NCT04209634
Locations
🇹🇷

Regeneron Research Site, Istanbul, Turkey

A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid

First Posted Date
2019-12-20
Last Posted Date
2024-05-01
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
98
Registration Number
NCT04206553
Locations
🇨🇳

Regeneron study Site, Taoyuan City, Taiwan

🇩🇪

Regeneron Study Site 2, Dresden, Saxony, Germany

🇵🇱

Regeneron Study site', Wroclaw, Poland

and more 2 locations

A Study to Evaluate the Effect of Dupilumab on Exercise Capacity in Adult Patients With Asthma

Phase 4
Completed
Conditions
Interventions
First Posted Date
2019-12-18
Last Posted Date
2024-04-18
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
40
Registration Number
NCT04203797
Locations
🇵🇱

Regeneron Study Site, Lubin, Dolnoslaskie, Poland

🇩🇪

IKF Pneumologie GmbH & Co. KG - Institut fuer klinische Forschung Pneumologie Frankfurt (Clinical Research Centre Respiratory Medicine) to IKF Pneumologie Frankfurt GmbH & Co KG., Frankfurt am Main, Hessen, Germany

🇩🇪

IKF Pneumologie Mainz, Helix Medical Excellence Center Mainz, Mainz, Rheinland-Pfalz, Germany

and more 21 locations
© Copyright 2024. All Rights Reserved by MedPath